目的 比較康柏西普與雷珠單抗治療視網(wǎng)膜中央靜脈阻塞（central retinal vein occlusion，CRVO）繼發(fā)黃斑水腫的效果和安全性。方法 將陜西省楊凌示范區(qū)醫(yī)院自2015年6月-2017年1月納入的CRVO繼發(fā)黃斑水腫患者102例作為研究對象，隨機(jī)分為兩組，即使用康柏西普治療的A組50例（50眼），使用雷珠單抗治療的B組52例（52眼），觀察治療后1、3、6個月時患者視力恢復(fù)情況和黃斑部視網(wǎng)膜厚度變化情況，評價不同藥物的治療效果和安全性。結(jié)果 治療6個月后A組患者視力提高率（52.00%）高于B組（30.77%），差異具有統(tǒng)計學(xué)意義（P<0.05）；兩組患者的黃斑部視網(wǎng)膜厚度的改善A組優(yōu)于B組，且各個復(fù)診時間點(diǎn)比較，差異均具有統(tǒng)計學(xué)意義（P<0.05）。兩組不良反應(yīng)發(fā)生率分別為8.00%和11.54%，差異無統(tǒng)計學(xué)意義。結(jié)論 康柏西普治療CRVO繼發(fā)黃斑水腫的臨床效果優(yōu)于雷珠單抗，但二者的安全性差異不顯著，有待于進(jìn)一步長期大樣本研究證實(shí)。

Objective To study the therapeutic effect and safety of Conbercept Ophthalmic Injection and Ranibizumab Injections in the treatment of retinal central venous obstruction (CRVO) macular edema.Methods 102 patients with CRVO macular edema admitted in our hospital from January 2014 to January 2017 were divided into two groups according to the order of admission. In group A, 50 patients (50 eyes) were treated with Conbercept Ophthalmic Injection. In group B, 52 patients (52 eyes) were treated with Ranibizumab Injections. After treatment, the changes of visual acuity and macular fovea were observed at 1 month, 3 months and 6 months after treatment. The therapeutic effect and safety of different drugs.Results The improvement rate of visual acuity was 52.00% in group A after 6 months of treatment, which was significantly higher than that in group B (30.77%). The difference was statistically significant (P< 0.05). After treatment, the retinal thickness improvement in the macular region of A group was better than that in the B group, and the differences were statistically significant (P< 0.05). The incidence of adverse reactions of the two groups were 8.00% and 11.54% respectively, the difference was not significant.Conclusion Conbercept Ophthalmic Injection and Ranibizumab Injections have good clinical effect and safety in patients with CRVO macular edema, the difference is not significant, and the clinical observation is needed to further expand the number of samples and the drug cycle.